share_log

Needham Maintains Buy on RxSight, Raises Price Target to $66

Benzinga ·  Aug 21 00:25  · Ratings

Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and raises the price target from $54 to $66.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment